197 related articles for article (PubMed ID: 12538800)
1. Pharmacokinetics and pharmacodynamics of entacapone and tolcapone after acute and repeated administration: a comparative study in the rat.
Forsberg M; Lehtonen M; Heikkinen M; Savolainen J; Järvinen T; Männistö PT
J Pharmacol Exp Ther; 2003 Feb; 304(2):498-506. PubMed ID: 12538800
[TBL] [Abstract][Full Text] [Related]
2. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration.
Forsberg MM; Huotari M; Savolainen J; Männistö PT
Eur J Pharm Sci; 2005 Apr; 24(5):503-11. PubMed ID: 15784340
[TBL] [Abstract][Full Text] [Related]
3. Effects of peripheral and central catechol-O-methyltransferase inhibition on striatal extracellular levels of dopamine: a microdialysis study in freely moving rats.
Napolitano A; Bellini G; Borroni E; Zürcher G; Bonuccelli U
Parkinsonism Relat Disord; 2003 Jan; 9(3):145-50. PubMed ID: 12573869
[TBL] [Abstract][Full Text] [Related]
4. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat.
Haasio K; Sopanen L; Vaalavirta L; Lindén IB; Heinonen EH
J Neural Transm (Vienna); 2001; 108(1):79-91. PubMed ID: 11261749
[TBL] [Abstract][Full Text] [Related]
5. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease.
Kaakkola S
Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464
[TBL] [Abstract][Full Text] [Related]
6. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans.
Dingemanse J; Jorga KM; Schmitt M; Gieschke R; Fotteler B; Zürcher G; Da Prada M; van Brummelen P
Clin Pharmacol Ther; 1995 May; 57(5):508-17. PubMed ID: 7768073
[TBL] [Abstract][Full Text] [Related]
7. Entacapone does not induce conformational changes in liver mitochondria or skeletal muscle in vivo.
Haasio K; Lounatmaa K; Sukura A
Exp Toxicol Pathol; 2002 Jul; 54(1):9-14. PubMed ID: 12180806
[TBL] [Abstract][Full Text] [Related]
8. COMT inhibition in the treatment of Parkinson's disease.
Ruottinen HM; Rinne UK
J Neurol; 1998 Nov; 245(11 Suppl 3):P25-34. PubMed ID: 9808337
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibition of lung cancer cell lines by (-)-epigallocatechin-3-gallate in combination with clinically used nitrocatechol inhibitors of catechol-O-methyltransferase.
Forester SC; Lambert JD
Carcinogenesis; 2014 Feb; 35(2):365-72. PubMed ID: 24148818
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson's disease therapy.
Jorga KM; Fotteler B; Heizmann P; Zürcher G
Eur J Clin Pharmacol; 1998 Jul; 54(5):443-7. PubMed ID: 9754991
[TBL] [Abstract][Full Text] [Related]
11. Different modes of action of catecholamine-O-methyltransferase inhibitors entacapone and tolcapone on adenylyl cyclase activity in vitro.
Gerlach M; Ukai W; Ozawa H; Riederer P
J Neural Transm (Vienna); 2002 May; 109(5-6):789-95. PubMed ID: 12111468
[TBL] [Abstract][Full Text] [Related]
12. Tissue and interspecies comparison of catechol-
Jalkanen A; Lassheikki V; Torsti T; Gharib E; Lehtonen M; Juvonen RO
Xenobiotica; 2021 Mar; 51(3):268-278. PubMed ID: 33289420
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
[TBL] [Abstract][Full Text] [Related]
14. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases.
Lautala P; Ethell BT; Taskinen J; Burchell B
Drug Metab Dispos; 2000 Nov; 28(11):1385-9. PubMed ID: 11038168
[TBL] [Abstract][Full Text] [Related]
15. Catechol-O-methyltransferase: variation in enzyme activity and inhibition by entacapone and tolcapone.
De Santi C; Giulianotti PC; Pietrabissa A; Mosca F; Pacifici GM
Eur J Clin Pharmacol; 1998 May; 54(3):215-9. PubMed ID: 9681662
[TBL] [Abstract][Full Text] [Related]
16. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase.
Kaakkola S; Gordin A; Männistö PT
Gen Pharmacol; 1994 Sep; 25(5):813-24. PubMed ID: 7835624
[TBL] [Abstract][Full Text] [Related]
17. Glucuronidation of entacapone, nitecapone, tolcapone, and some other nitrocatechols by rat liver microsomes.
Lautala P; Kivimaa M; Salomies H; Elovaara E; Taskinen J
Pharm Res; 1997 Oct; 14(10):1444-8. PubMed ID: 9358559
[TBL] [Abstract][Full Text] [Related]
18. Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym(®), a Mechanistic Model of Drug-Induced Liver Injury.
Longo DM; Yang Y; Watkins PB; Howell BA; Siler SQ
CPT Pharmacometrics Syst Pharmacol; 2016 Jan; 5(1):31-9. PubMed ID: 26844013
[TBL] [Abstract][Full Text] [Related]
19. Differences in toxicity of the catechol-O-methyl transferase inhibitors, tolcapone and entacapone to cultured human neuroblastoma cells.
Korlipara LV; Cooper JM; Schapira AH
Neuropharmacology; 2004 Mar; 46(4):562-9. PubMed ID: 14975680
[TBL] [Abstract][Full Text] [Related]
20. The central catechol-O-methyltransferase inhibitor tolcapone increases striatal hydroxyl radical production in L-DOPA/carbidopa treated rats.
Gerlach M; Xiao AY; Kuhn W; Lehnfeld R; Waldmeier P; Sontag KH; Riederer P
J Neural Transm (Vienna); 2001; 108(2):189-204. PubMed ID: 11314772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
